領航醫藥生物科技(00399.HK)擬發行本金額5550萬港元可換股債券
格隆匯7月28日丨領航醫藥生物科技(00399.HK)發佈公吿,2023年7月27日,公司與認購人(即毛裕民博士)訂立認購協議,據此,認購人有條件同意認購本金額為5550萬港元的可換股債券。假設可換股債券按換股價每股轉換股份0.211港元(可予調整)獲悉數轉換,則將會配發及發行最多約2.63億股轉換股份,相當於本公吿日期公司已發行股本約17.96%及經配發及發行轉換股份擴大的已發行股本約15.23%。
認購協議項下應由認購人支付為數5550萬港元的認購價,將以按等額基準悉數抵銷公司根據股東貸款應向認購人支付的未償還本金總額5550萬港元的方式繳付。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.